Earnings GrowthAptarGroup is well-positioned to deliver a high-quality earnings growth algorithm, driven by growth in Pharmaceuticals and cost-out initiatives in Packaging.
Product DevelopmentAptarGroup is significantly outspending its peers on new product development, which is expected to result in a 10% compound annual growth rate in Pharma segment sales through 2027.
Share RepurchaseThe $500 million share repurchase authorization is notable, supported by a balance sheet with minimal leverage and potential for strategic acquisitions.